Evolocumab Lowered Cardiovascular Risk After Bypass Surgery
In a 2026 study, the drug reduced major heart events for patients who had bypass surgery but no prior heart attack.
Updated on Oct. 12, 2026 in Heart Disease
Live Poll
Should doctors aggressively use additional drug therapies to prevent future heart issues after bypass surgery?
Researchers found that evolocumab significantly lowered the risk of major cardiovascular events in patients with a history of coronary artery bypass grafting who had never experienced a myocardial infarction. These findings were presented at the 2026 EACTS meeting in Barcelona.
Why it matters
Patients who have undergone bypass surgery without a prior heart attack face elevated cardiovascular risks, making effective lipid management critical. This study highlights a strategy to address those specific risks after initial surgical intervention.
In a randomized trial of 1,432 patients with a mean age of 68, those receiving evolocumab saw a 28% lower risk of major cardiovascular events compared to placebo. The drug also demonstrated a 56% reduction in LDL cholesterol levels over a median follow-up of 4.5 years.
The players
EACTS
The European Association for Cardio-Thoracic Surgery is a professional organization dedicated to advancing cardiac and thoracic surgery through research and education.
The details
Evolocumab acts as a PCSK9 inhibitor, working to lower LDL cholesterol levels significantly by increasing the number of receptors available to clear cholesterol from the bloodstream. In this study, patients received 140 mg of the medication subcutaneously every two weeks. This sustained reduction in LDL cholesterol appears to contribute to the observed decrease in four-point major cardiovascular events, which included coronary heart disease death and ischemic stroke.
Timeline
In 2026, study findings were presented at the EACTS meeting in Barcelona.
Health Landscape
This study aligns with the EACTS clinical research and scientific presentation series regarding long-term outcomes for post-surgical cardiac patients. It provides a targeted approach for those who require intensified lipid management following coronary artery bypass grafting.
If you have undergone a coronary artery bypass graft, you may be at higher risk for future cardiovascular events even without a prior heart attack. These findings are worth discussing with your cardiologist to understand if current lipid-lowering strategies are optimal for your care plan.
The takeaway
The study suggests that evolocumab provides significant cardiovascular protection for specific post-surgical populations. Always consult your physician about your individual cholesterol targets and the appropriate treatment options for your specific cardiac history.
Further reading
For more on managing heart health, visit our Heart Disease section.
Source note: This article includes information reported by Tctmd.
Live Poll
Should doctors aggressively use additional drug therapies to prevent future heart issues after bypass surgery?
